Short answer
Cogent Biosciences, Inc. (COGT) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 8.01 (Other Events). $400M at-the-market equity offering capacity added through Guggenheim Securities.
Cogent Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $400M at-the-market equity offering capacity added through Guggenheim Securities
- Common shares may be sold periodically at prevailing market prices
- Potential dilution and share-price pressure for existing shareholders
- Proceeds provide Cogent with flexible funding for operations and development programs
- Automatic shelf registration effective November 7, 2025, enabling immediate issuanceյութ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cogent Biosciences, Inc. 8-K filings
Get the next COGT 8-K as it lands
Follow COGT for push alerts, or ask the research agent what this filing means.